Blindness Clinical Trial
Official title:
Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation
The purpose of this study is to evaluate the use of an artificial vision system called Brainport system in blind patients To investigate visual, and oculomotor (eye motion) mechanisms involved in the use of the Brainport system.
The prevalence of blindness in the US adult population is 0.8% and ranges from about 3/10000 to 15/10000 in children. Data from world health organization show that about 500,000 children become blind each year. The annual cost of blindness to the federal government is $4 billion and the cost of a lifetime of support and unpaid taxes for a blind person is about $1 million. There is a need to restore vision for blind patients. Research on vision restoration develops fast. There are multiple types of approaches toward producing useful artificial vision. One of them directly sends images from a video camera to the visual cortex via an electrode array that is intracranially placed on the visual cortex of blind patients. Another one surgically places an electrode array beneath the retina for patients whose optic nerves are still healthy. Both of them require major surgery and have high risks, and neither is available for routine clinical application. The one that is non-invasive and easy to use is called the BrainPort® system. The BrainPort® system is manufactured by Wicab, Inc. It is commercially available and affordable to any consumer. This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02393118 -
A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury
|
N/A | |
| Terminated |
NCT00262509 -
Emergency Egress and Information System for Persons With Vision Loss
|
N/A | |
| Terminated |
NCT00691444 -
Blind Child Melatonin Treatment Study
|
N/A | |
| Recruiting |
NCT06237829 -
Testing Tactile Aids With Blind Subjects
|
N/A | |
| Completed |
NCT00829036 -
Wayfinding Information Access System for People With Vision Loss
|
N/A | |
| Completed |
NCT01488786 -
A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind
|
N/A | |
| Recruiting |
NCT00403143 -
Do Blue-Blocking Lenses Block Blue Colour From Our Lives?
|
N/A | |
| Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
| Recruiting |
NCT04725760 -
Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population
|
N/A | |
| Recruiting |
NCT02983370 -
Development of a Cortical Visual Neuroprosthesis for the Blind
|
N/A | |
| Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|
||
| Completed |
NCT00920231 -
Computer Vision System for the Blind Veteran
|
Phase 1 | |
| Completed |
NCT01109576 -
Workshops for Veterans With Vision and Hearing Loss
|
Phase 0 | |
| Terminated |
NCT00795236 -
Melatonin Studies of Totally Blind Children
|
N/A | |
| Terminated |
NCT00634972 -
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
|
Phase 4 | |
| Enrolling by invitation |
NCT06364605 -
MySpace: the Role of Vision in Representing Space
|
N/A | |
| Terminated |
NCT03913130 -
Extension Study to Study PQ-110-001 (NCT03140969)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05806684 -
Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.
|
||
| Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
| Recruiting |
NCT04855045 -
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
|
Phase 2/Phase 3 |